1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Opsens Inc.
  6. News
  7. Summary
    OPS   CA6838231083

OPSENS INC.

(OPS)
  Report
Delayed Toronto Stock Exchange  -  05/20 04:00:00 pm EDT
1.930 CAD   +0.52%
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/19OPSENS SAVVYWIRE™ FIRST-IN-HUMAN RESULTS PRESENTED AT EUROPCR IN PARIS AND SIMULTANEOUSLY PUBLISHED IN EUROINTERVENTION JOURNAL
AQ
05/19Opsens Inc. Announces New Data Supporting the Safety and Efficacy of its SavvyWire Recently Approved by Health Canada for Transcatheter Aortic Valve Replacement Procedures
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Opsens : 52-109 F2 CFO Certification

01/13/2022 | 11:21am EDT

FORM 52-109F2

CERTIFICATION OF INTERIM FILINGS

FULL CERTIFICATE

I, Robin Villeneuve, Chief Financial Officer of Opsens Inc., certify the following:

  1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Opsens Inc. (the "issuer") for the interim period ended November 30, 2021.
  2. No misrepresentations: Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.
  3. Fair presentation: Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.
  4. Responsibility: The issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in Regulation 52-109respecting Certification of Disclosure in Issuers' Annual and Interim Filings (c. V-1.1, r. 27), for the issuer.
  5. Design: Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings
    1. designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that
      1. material information relating to the issuer is made known to us by
        others, particularly during the period in which the interim filings are being prepared; and
      2. information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
    2. designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.
  1. Control framework: The control framework the issuer's other certifying officer(s) and I used to design the issuer's ICFR is Committee of Sponsoring Organizations of the Treadway Commission (COSO).
  2. N/A
  3. N/A

6. Reporting changes in ICFR: The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on September 1st, 2021 and ended on November 30, 2021 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: January 13, 2022

  1. Robin Villeneuve, CPA, CARobin Villeneuve
    Chief Financial Officer Opsens Inc.

Disclaimer

OPSENS Inc. published this content on 13 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 January 2022 16:20:01 UTC.


© Publicnow 2022
All news about OPSENS INC.
05/19Opsens Presents Results of First-in-human Study of SavvyWire at European Conf
MT
05/19OPSENS SAVVYWIRE™ FIRST-IN-HUMAN RESULTS PRESENTED AT EUROPCR IN PARIS AND SIMULT..
AQ
05/19Opsens Inc. Announces New Data Supporting the Safety and Efficacy of its SavvyWire Rece..
CI
05/18Opsens Announces Publication of New Optowire Data in Journal
MT
05/18Opsens announces publication in jscai of data supporting the correlation between the op..
AQ
04/26OpSens Announces Health Canada Approval For Its New TAVR Guidewire
MT
04/26Opsens announces health canada approval for its new tavr guidewire
AQ
04/26Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire
CI
04/13TRANSCRIPT : Opsens Inc., Q2 2022 Earnings Call, Apr 13, 2022
CI
04/13OPSENS : CFO Certification
PU
More news
Analyst Recommendations on OPSENS INC.
More recommendations
Financials
Sales 2022 36,6 M 28,5 M 28,5 M
Net income 2022 -7,29 M -5,68 M -5,68 M
Net Debt 2022 - - -
P/E ratio 2022 -28,6x
Yield 2022 -
Capitalization 209 M 163 M 163 M
Capi. / Sales 2022 5,72x
Capi. / Sales 2023 3,85x
Nbr of Employees 163
Free-Float 95,0%
Chart OPSENS INC.
Duration : Period :
Opsens Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OPSENS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 1,93 CAD
Average target price 4,22 CAD
Spread / Average Target 119%
EPS Revisions
Managers and Directors
Louis Laflamme President, Chief Executive Officer & Director
Robin Villeneuve Chief Financial Officer & Secretary
Alan W. Milinazzo Executive Chairman
Jean Lavigueur Independent Director
Denis L. Harrington Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OPSENS INC.-37.74%163
THERMO FISHER SCIENTIFIC-17.46%217 320
DANAHER CORPORATION-23.47%180 262
INTUITIVE SURGICAL, INC.-39.03%78 637
SIEMENS HEALTHINEERS AG-16.99%64 649
EDWARDS LIFESCIENCES CORPORATION-27.19%58 644